Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs.

[1]  Diana N. Carvajal,et al.  Contraceptive Decision-Making and the Importance of Side Effect Information Among a Sample of Latinas , 2022, Women's health reports.

[2]  T. Faustmann,et al.  Thirty years of mirena: A story of innovation and change in women’s healthcare , 2021, Acta obstetricia et gynecologica Scandinavica.

[3]  D. Apter,et al.  Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route , 2020, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[4]  C. Westhoff,et al.  Six-Year Contraceptive Efficacy and Continued Safety of a Levonorgestrel 52mg Intrauterine System. , 2019, Contraception.

[5]  W. Jusko,et al.  Altered pharmacokinetics of combined oral contraceptives in obesity - multistudy assessment. , 2019, Contraception.

[6]  H. Drenth,et al.  An Integrated Population Pharmacokinetic Analysis to Characterize Levonorgestrel Pharmacokinetics After Different Administration Routes , 2018, Journal of clinical pharmacology.

[7]  W. H. Pearse,et al.  American College of Obstetricians and Gynecologists , 2018, Definitions.

[8]  A. Nelson.  LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years , 2017, Expert opinion on drug delivery.

[9]  T. Faustmann,et al.  Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. , 2017, European journal of obstetrics, gynecology, and reproductive biology.

[10]  W. Jusko.  Clarification of contraceptive drug pharmacokinetics in obesity. , 2017, Contraception.

[11]  D. Costescu.  Levonorgestrel-releasing intrauterine systems for long-acting contraception: current perspectives, safety, and patient counseling , 2016, International journal of women's health.

[12]  D. Bloom,et al.  Economic Benefits of Investing in Women’s Health: A Systematic Review , 2016, PloS one.

[13]  C. Westhoff,et al.  Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. , 2015, Contraception.

[14]  D. Apter,et al.  Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. , 2014, Fertility and sterility.

[15]  K. Black,et al.  Worldwide use of intrauterine contraception: a review. , 2014, Contraception.

[16]  D. Apter,et al.  Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: A Randomized Controlled Trial , 2013, Obstetrics and gynecology.

[17]  K. Grumbach,et al.  Women's preferences for contraceptive counseling and decision making. , 2013, Contraception.

[18]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods , 2013, CPT: pharmacometrics & systems pharmacology.

[19]  D. Apter,et al.  A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. , 2012, Fertility and sterility.

[20]  F. Stanczyk,et al.  Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. , 2010, Contraception.

[21]  T. Backman,et al.  The levonorgestrel intrauterine system in contraception , 2000, Steroids.

[22]  K. Fotherby.  Levonorgestrel. Clinical pharmacokinetics. , 1995, Clinical pharmacokinetics.

[23]  W. Kuhnz,et al.  Influence of changes in the concentration of sex hormone-binding globulin in human serum on the protein binding of the contraceptive steroids levonorgestrel, 3-keto-desogestrel and gestodene , 1994, Journal of Steroid Biochemistry and Molecular Biology.

[24]  E. Johansson,et al.  Plasma levels of d-norgestrel, estradiol and progesterone during treatment with silastic implants containing d-norgestrel. , 1976, Contraception.

[25]  D. Mishell,et al.  Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration. , 1975, Contraception.